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BACKGROUND: The proﬁle of cortical neuroanatomical abnormalities in schizophrenia is not fully understood,
despite hundreds of published structural brain imaging studies. This study presents the ﬁrst meta-analysis of cortical
thickness and surface area abnormalities in schizophrenia conducted by the ENIGMA (Enhancing Neuro Imaging
Genetics through Meta Analysis) Schizophrenia Working Group.
METHODS: The study included data from 4474 individuals with schizophrenia (mean age, 32.3 years; range, 11–78
years; 66% male) and 5098 healthy volunteers (mean age, 32.8 years; range, 10–87 years; 53% male) assessed with
standardized methods at 39 centers worldwide.
RESULTS: Compared with healthy volunteers, individuals with schizophrenia have widespread thinner cortex (left/
right hemisphere: Cohen’s d = 20.530/20.516) and smaller surface area (left/right hemisphere: Cohen’s d = 20.251/
20.254), with the largest effect sizes for both in frontal and temporal lobe regions. Regional group differences in
cortical thickness remained signiﬁcant when statistically controlling for global cortical thickness, suggesting regional
speciﬁcity. In contrast, effects for cortical surface area appear global. Case-control, negative, cortical thickness effect
sizes were two to three times larger in individuals receiving antipsychotic medication relative to unmedicated
individuals. Negative correlations between age and bilateral temporal pole thickness were stronger in individuals
with schizophrenia than in healthy volunteers. Regional cortical thickness showed signiﬁcant negative correlations
with normalized medication dose, symptom severity, and duration of illness and positive correlations with age at
onset.
CONCLUSIONS: The ﬁndings indicate that the ENIGMA meta-analysis approach can achieve robust ﬁndings in
clinical neuroscience studies; also, medication effects should be taken into account in future genetic association
studies of cortical thickness in schizophrenia.
Keywords: Cortical, Imaging, Meta-analysis, Schizophrenia, Surface area, Thickness
https://doi.org/10.1016/j.biopsych.2018.04.023Brain structural abnormalities are widely reported in schizo-
phrenia, but there is no published meta-analysis reporting ef-
fect sizes for cortical thickness and surface area abnormalities
and their relationships to clinical features of the disease.
Several hundred studies have reported on cortical thickness
and surface area abnormalities in schizophrenia, but it is
difﬁcult to meta-analyze published results, as they lack a
standard format to ease comparisons and are based on atlas
(1) or vertex-wise (2) approaches using a variety of methods
(3–9). To address these issues, the Schizophrenia Working
Group within the ENIGMA (Enhancing Neuro Imaging Genetics
through Meta Analysis; http://enigma.ini.usc.edu) (10–12)
consortium brings together schizophrenia researchers from
all over the world to jointly conduct large-scale imaging and
imaging/genetics meta-analyses using standardized methods.
This meta-analysis focuses on regional cortical thickness
and surface area rather than volume, based on evidence that
they are inﬂuenced by separate sets of genes (13,14). Cortical
thickness and surface area abnormalities have been reported in
individuals with chronic (1,15–17), short- or medium-duration
(18), ﬁrst-episode (19–24), child-onset (25,26), adolescent-
onset (27), and antipsychotic-naïve (28–30) schizophrenia;
individuals with nonclinical psychotic symptoms (31); and in-
dividuals at clinical high risk for psychosis (32–39).
We previously reported effect sizes for deep brain structure
volume abnormalities based on 15 samples worldwide,
including brain imaging data from 2028 individuals with
schizophrenia and 2540 healthy volunteers (40); ﬁndings were
replicated in an independent cohort using similar methods (41).
Here we report Cohen’s d effect sizes comparing regional
cortical thickness and surface area between 4474 individualsBiological Psycwith schizophrenia and 5098 healthy volunteers, and partial
correlation effect sizes with continuous clinical measures
based on 39 worldwide samples. Based on prior work, we
hypothesized that individuals with schizophrenia, compared
with healthy volunteers, show widespread cortical thickness
and surface abnormalities that are most prominent in frontal
and temporal lobe regions (15) and that show signiﬁcant
associations with age at onset or duration of illness (42),
symptom severity (43–48), and antipsychotic medication use
(49–51).
METHODS AND MATERIALS
Study Samples
Via the ENIGMA Schizophrenia Working Group, 39 worldwide,
cross-sectional study samples totaling 9572 participants,
including 4474 individuals with schizophrenia and 5098 healthy
volunteers, contributed to the analysis (Tables S1a and S1b
and Figure S1 in Supplement 1). Sample-size weighted mean
(range) age across samples was 32.3 (21.2–43.6) years for in-
dividuals with schizophrenia and 34.5 (21.8–43.9) years for
healthy volunteers. Patient and control samples were on
average 65% (44–100) and 54% (36–100) male. Weighted
mean age at onset and duration of illness across the samples
were 23.4 (20.0–35.6) years and 10.5 (0.6–20.2) years.
Weighted mean Positive and Negative Syndrome Scale
(PANSS) (52) total, negative, and positive scores across the
samples were 68.1 (43.0–90.2), 21.9 (10.0–22.9), and 16.4
(10.6–22.6); weighted mean Scale for the Assessment of
Negative Symptoms (53) and Scale for the Assessment of
Positive Symptoms (54) scores were 20.5 (5.5–33.0) and 19.2hiatry November 1, 2018; 84:644–654 www.sobp.org/journal 645
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antipsychotic type and/or dose, numbers (percentages) of
patients on second-generation (atypical), ﬁrst-generation
(typical), both second-generation and ﬁrst-generation, or no
(unmedicated) antipsychotic medications were 2236 (66%),
447 (13%), 265 (8%), and 425 (13%), and sample-size
weighted mean chlorpromazine dose equivalent, based on
Woods’ calculations (www.scottwilliamwoods.com/ﬁles/
Equivtext.doc), was 399 (167–643). Each study sample was
collected with participants’ written informed consent approved
by local institutional review boards.
Image Acquisition and Processing
All sites processed T1-weighted structural brain scans using
FreeSurfer (9) (http://surfer.nmr.mgh.harvard.edu) and extrac-
ted cortical thickness and surface area for 70 Desikan-Killiany
(DK) atlas regions (55) (34 regions per hemisphere 1 left and
right hemisphere mean thickness or total surface area)
(Table S3 in Supplement 1). Number of scanners, vendor,
strength, sequence, acquisition parameters, and FreeSurfer
versions are provided in Table S2 in Supplement 1. ENIGMA’s
quality assurance protocol was performed at each site before
analysis and included visual checks of the cortical segmenta-
tions and region-by-region removal of values for segmenta-
tions found to be incorrect (http://enigma.usc.edu/protocols/
imaging-protocols) (Table S2 in Supplement 1). Histograms
of all regions’ values for each site were also computed for vi-
sual inspection.
Statistical Meta-analyses
Group differences for DK atlas regions within each sample
were examined using univariate linear regression (R linear
model function lm; R Foundation for Statistical Computing,
Vienna, Austria) predicting left and right DK atlas region cortical
thickness or surface area with group (individuals with schizo-
phrenia, healthy volunteers), gender, and age (model A). To
further assess whether group differences in cortical thickness
and surface area showed regional speciﬁcity, analyses were
repeated including global mean cortical thickness and total
cortical surface area as covariates, respectively (model B). To
test for differential gender or age effects between groups, we
also included models with group-by-gender (model C) or
group-by-age interaction terms (model D). Signiﬁcant in-
teractions were further explored through within-group ana-
lyses. Medication effects were examined through between-646 Biological Psychiatry November 1, 2018; 84:644–654 www.sobp.ogroup comparisons of individuals with schizophrenia on
second-generation (atypical), ﬁrst-generation (typical), both
second-generation and ﬁrst-generation, or no (unmedicated)
antipsychotic medications and healthy volunteers with gender
and age included as covariates; only contrasts with a minimum
of 5 subjects per group within site were included in these an-
alyses to enable variance estimation. In patients, relationships
were examined between regional cortical measures and
several continuous variables, including age at onset; duration
of illness; chlorpromazine equivalent antipsychotic medication
dose; and total, positive, and negative symptom severity.
These partial correlation analyses included age and gender as
covariates. Analysis of multiscanner studies (ASRB, FBIRN,
MCIC, Osaka, UPENN) included binary dummy covariates for
n-1 scanners. Sites conducted analyses of their sample’s in-
dividual subject data using R code created within the ENIGMA
collaboration. Random-effects meta-analyses of Cohen’s
d and partial correlation effect sizes for each of the DK atlas
regions were performed using R (version 3.2.2) metafor pack-
age (version 1.9-7) (56). False discovery rate (FDR) (pFDR , .05)
(57) was used to control for multiple comparisons. Cortical
maps depict signiﬁcant effect sizes (pFDR , .05) overlaid on
(metallic gray) cortical surface models (https://brainder.org/
research/brain-for-blender). Possible confounding effects of
differences in parental socioeconomic status on group differ-
ences were examined using subsample analyses (see Results
SR3, Figures, and Tables S8a and S9b, and S52a and S53b in
Supplement 1). Effects of FreeSurfer version and scanner ﬁeld
strength were examined using meta-regressions (Supplement 1).
RESULTS
Widespread Thinner Cortex With Regional
Speciﬁcity in Schizophrenia
Individuals with schizophrenia, compared with healthy volun-
teers, showed widespread signiﬁcantly thinner cortex in all DK
atlas regions except the bilateral pericalcarine region (model
A), with effect sizes between Cohen’s d = 20.536 (right fusi-
form gyrus) and Cohen’s d = 20.077 (left pericalcarine ﬁssure)
and marginal (least square) mean thickness differences
between 23.33% (left parahippocampal gyrus) and 20.45%
(left pericalcarine ﬁssure) (Figure 1A and Table S4a in
Supplement 1). The largest negative effect sizes (Cohen’s
d , 20.40) were observed for left/right hemisphere (Cohen’s
d = 20.530/20.516); bilateral fusiform, temporal (inferior,Figure 1. Cortical map of regional Cohen’s d
effect sizes for schizophrenia subjects’ vs. healthy
volunteers’ cortical thickness contrast statistically
controlling for age and gender (A) and age, gender,
and global cortical thickness (B). Only regions with
pfalse discovery rate , .05 are depicted in color. In panel
(B), warm colors (yellow-red) reﬂect regions in which
the effect of schizophrenia is more than the mean
global cortical thinning, and cool colors (green-blue)
reﬂect regions where the effect of schizophrenia is
less than the mean global thinning compared with
healthy volunteers.
rg/journal
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opercularis; and bilateral insula.
In the context of widespread thinner cortex in schizophrenia,
we assessed regional speciﬁcity of these cortical thickness
differences. When controlling for individual differences in global
mean cortical thickness, several regions showed signiﬁcantly
thinner cortex (e.g., fusiform, parahippocampal, inferior tem-
poral gyri), whereas other regions showed signiﬁcantly thicker
cortex (e.g., superior parietal cortex, precuneus, paracentral
lobule) in individuals with schizophrenia compared with healthy
volunteers (model B) (Figures 1B and Figure 2; Table S4b in
Supplement 1). These ﬁndings suggest regional speciﬁcity of
thinner cortex in schizophrenia.
Widespread Smaller Cortical Surface Area Without
Regional Speciﬁcity in Schizophrenia
Individuals with schizophrenia, compared with healthy in-
dividuals, showed widespread signiﬁcantly smaller cortical
surface area in all DK atlas regions except the bilateral isthmus
cingulate region (model A), with effect sizes between Cohen’s
d = 20.254 (mean right hemisphere) and Cohen’s d = 20.040
(right isthmus cingulate) and marginal (least square) mean sur-
face area differences between 23.39% (left rostral anterior
cingulate) and 20.55% (right isthmus cingulate) (Figure 3A;
Table S5a in Supplement 1). The largest effect sizes (Cohen’s
d , 20.20) were observed for left (Cohen’s d = 20.251) and
right (Cohen’s d = 20.254) hemisphere and bilateral superior
frontal, fusiform, inferior and middle temporal, and right pre-
central gyri.
In the context of widespread smaller cortical surface area in
schizophrenia, we assessed regional speciﬁcity of these
cortical surface area differences. When controlling for individ-
ual differences in total cortical surface area, no regions showed
signiﬁcantly smaller surface area, whereas three regions
showed signiﬁcantly larger cortical surface area (bilateral
isthmus cingulate, precuneus, and left paracentral) in in-
dividuals with schizophrenia compared with healthy volunteersBiological Psyc(model B) (Figure 3B; Table S5b in Supplement 1). These
ﬁndings suggest that smaller cortical surface area is predom-
inantly global in schizophrenia except for the three regions
noted, which appear less affected.
Group-by-Gender Interactions
No signiﬁcant group-by-gender interactions were detected for
either cortical thickness or surface area for any of the DK atlas
regions (Tables S6 and S7 in Supplement 1).
Group-by-Age Interactions
There were signiﬁcant group-by-age interactions for both left
(pFDR = .007) and right (pFDR = .01) temporal pole thickness,
with individuals with schizophrenia showing stronger negative
correlations with age (left, r = 2.13, pFDR = 1.51E-13; right,
r = 2.12, pFDR = 1.55E-07) than healthy volunteers (left,
r = 2.05, pFDR = .02; right, r = 2.04, pFDR = .03). These in-
teractions remained signiﬁcant even when controlling for
global mean cortical thickness (Figure S2 and Tables S8a, S8b,
S10, and S11 in Supplement 1). There were no signiﬁcant
group-by-age interactions for cortical surface area for any of
the DK atlas regions (Table S9 in Supplement 1).
Partial Correlations With Age of Onset and Duration
of Illness
Earlier age of onset (r = .063, pFDR = .03) and longer duration of
illness (r = 2.061, pFDR = .04) were signiﬁcantly correlated with
thinner right insula cortical thickness (Tables S33 and S34 and
Figure S3 in Supplement 1). There were no signiﬁcant corre-
lations between age of onset or duration of illness and cortical
surface area for any of the DK atlas regions (Tables S43 and
S44 in Supplement 1).
Effects of Antipsychotic Medications on Cortical
Thickness
Effect sizes comparing left and right hemisphere cortical
thickness from individuals with schizophrenia on noFigure 2. Cohen’s d effect sizes for schizophrenia
subjects’ vs. healthy volunteers’ cortical thickness
contrast statistically controlling for age, gender, and
global mean cortical thickness. Only regions with
pfalse discovery rate , .05 are depicted in color.
hiatry November 1, 2018; 84:644–654 www.sobp.org/journal 647
Figure 3. Cortical map of regional Cohen’s d ef-
fect sizes for schizophrenia subjects vs. healthy
volunteers’ cortical surface area contrast statistically
controlling for age and gender (A) and age, gender,
and total cortical surface area (B). Only regions with
pfalse discovery rate , .05 are depicted in color. In panel
(B), warm colors (yellow-red) reﬂect regions in which
the effect of schizophrenia is more than the mean
lower surface area, and cool colors (green-blue)
reﬂect regions where the effect of schizophrenia is
less than the mean lower global surface area
compared with healthy volunteers.
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Psychiatry(unmedicated; left/right, Cohen’s d = 20.275/20.278),
second-generation (left/right, Cohen’s d = 20.536/20.516),
ﬁrst-generation (left/right, Cohen’s d = 20.765/20.648), or
both second-generation and ﬁrst-generation (left/right
Cohen’s d = 20.770/20.704) antipsychotic medications with
healthy volunteers were signiﬁcant for all but the unmedi-
cated group (pFDR . .05) (Figure 4; Tables S12–S15 in
Supplement 1).
Groupwise comparisons of left and right hemisphere
thickness found nominally signiﬁcant effects for all medicated
versus unmedicated groups (Figure 4; Tables S16–S18 in
Supplement 1). Similarly, nominally signiﬁcant effects were
found for ﬁrst-generation versus second-generation and both
second-generation and ﬁrst-generation versus second-
generation medication groups, but not both versus ﬁrst-
generation medication groups (Figure 4; Tables S19–S21 in
Supplement 1). No signiﬁcant regional effects were observed
for the last four group contrasts (pFDR . .05) (Tables S18–S21
in Supplement 1). For detailed regional effects of antipsychoticFigure 4. Cohen’s d effect sizes (A) and least square mean percent differenc
cortical thickness statistically controlling for age and gender by medication group
thickness group comparisons statistically controlling for age and gender were a
ﬁrst-generation vs. unmedicated (left, p , .01; right, p , .002); both ﬁrst-genera
ﬁrst-generation vs. second-generation (left, p , .03; right, p , .03); both ﬁrst-ge
p , .05); both ﬁrst-generation and second-generation vs. ﬁrst-generation (left, p
648 Biological Psychiatry November 1, 2018; 84:644–654 www.sobp.omedications on cortical thickness and surface area, see
Results SR1 in Supplement 1.
Partial Correlations With Medication Dose
Higher chlorpromazine dose equivalents were signiﬁcantly
correlated with thinner cortex in almost all the DK atlas regions
except bilateral entorhinal and pericalcarine cortex; bilateral
lingual and transverse temporal gyri; left postcentral, cuneus,
and parahippocampal gyri; caudal anterior cingulate cortex;
right superior parietal and rostral anterior cingulate cortex; and
right frontal pole (Figure S6A and Table S32 in Supplement 1).
The correlations were signiﬁcant for both left (r = 2.126) and
right (r = 2.126) hemisphere thickness and were strongest
(partial r,2.10) for left (r =2.166) and right (r =2.148) superior
frontal, left (r =2.113) and right (r =2.108) middle temporal, left
(r = 2.112) and right (r = 2.106) superior temporal, right inferior
temporal (r = 2.113), right pars triangularis of inferior frontal
(r = 2.113), left (r = 20.102) and right (r = 2.108) caudal middle
frontal, and left supramarginal (r = 2.103) gyri.e (B) for schizophrenia subjects vs. healthy volunteers contrasts in global
and hemisphere. Nominal one-tailed p values for left and right hemisphere
s follows: second-generation vs. unmedicated (left, p , .05; right, p , .06);
tion and second-generation vs. unmedicated (left, p , .02; right, p , .05);
neration and second-generation vs. second-generation (left, p , .02; right,
= .50; right, p = .48) (Tables S16–S21 in Supplement 1).
rg/journal
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promazine dose equivalents were signiﬁcantly correlated with
thinner cortex even when controlling for negative symptom
severity (Table S41 and Figure S7 in Supplement 1). There
were no detectable correlations between chlorpromazine dose
equivalents and cortical surface area for any of the DK atlas
regions (Table S42 in Supplement 1).
Partial Correlations With Symptom Severity Scores
Higher PANSS total and positive symptom severity scores
were signiﬁcantly correlated with regional thinner cortex
(Figure S6B, Table S35, Figure S6D, and Table S36 in
Supplement 1), whereas higher PANSS negative symptom
scores were signiﬁcantly correlated with widespread thinner
cortex in left (r = 2.085) and right (r = 2.089) hemispheres
(Figure S6C and Table S37 in Supplement 1; see Results SR2
in Supplement 1 for details). PANSS total, positive, and
negative symptom severity scores were not signiﬁcantly
correlated with regional cortical surface area for any of the DK
atlas regions (Tables S45–S47 in Supplement 1).
DISCUSSION
The main ﬁndings of this study are that individuals with
schizophrenia, compared with healthy volunteers, show the
following: 1) widespread thinner cortex (left/right, Cohen’s
d = 20.530/20.516); 2) widespread smaller cortical surface
area, about half the size of the effect observed for cortical
thickness (left/right Cohen’s d =20.251/20.254); 3) the largest
effect sizes in frontal and temporal lobe regions for both
measures, with regional speciﬁcity for cortical thickness, but
not cortical surface area (based on the analyses controlling for
global thickness and surface area); 4) approximately two times
larger negative cortical thickness effect size when on second-
generation antipsychotic medications (left/right, Cohen’s
d = 20.536/20.516) and approximately three times larger
cortical thickness effect size when on ﬁrst-generation (left/
right, Cohen’s d =20.765/20.648) or both ﬁrst-generation and
second-generation (left/right, Cohen’s d = 20.770/20.704)
antipsychotic medications relative to unmedicated individuals
with schizophrenia (left/right, Cohen’s d = 20.275/20.278);
and 5) a stronger negative correlation between age and bilat-
eral temporal pole cortical thickness (left, r = 2.13 vs. r = 2.05;
right, r = 2.12 vs. r = 2.04). With regard to partial correlations
with clinical variables, 6) earlier age at onset and longer
duration of illness were associated with thinner insula cortex; 7)
standardized medication dose (chlorpromazine dose equiva-
lent) and 8) negative symptom severity were associated with
widespread thinner cortex; and 9) total and 10) positive
symptom severity were associated with regional thinner cortex.
Most observed correlations were small (r , .2). Moreover,
despite the high power to detect small effects, medication use
and other clinical variables were not signiﬁcantly associated
with cortical surface area.
These ﬁndings are consistent with the interpretation that the
thinner cortex observed in individuals with schizophrenia
shows regional speciﬁcity and is associated with the disease
(28–30), its severity (43–48), and antipsychotic medication
treatment (49–51), with a larger effect for ﬁrst-generation
compared with second-generation antipsychotic medicationsBiological Psyc(16,58–60). We cannot fully exclude the possibility that
observed medication effects on cortical thickness are partially
due to group differences in age or duration of illness (61),
which also show patterns of increase across the groups.
However, such an interpretation is rendered unlikely by the
facts that 1) age was statistically controlled for in the medi-
cation type analyses; 2) duration of illness, which is highly
collinear with age, showed effects above and beyond age only
on right insula thickness; 3) there was only a group-by-age
interaction on temporal pole thickness (while medication ef-
fects were widespread); and 4) meta-regressions showed no
effects of age or duration of illness on group contrast effect
sizes (see Results SR1 in Supplement 1). Furthermore, disso-
ciating medication effects from other potentially confounding
variables requires well-powered, ﬁrst-episode longitudinal
studies, preferably with random assignment to ﬁrst-generation
or second-generation antipsychotics. Two longitudinal imag-
ing studies that randomly assigned individuals to medication
treatments found signiﬁcant gray matter reductions for halo-
peridol but not olanzapine (58,62); these ﬁndings are consis-
tent with our meta-analysis and with reported medication
effects on cortical thickness in rodents (63).
None of the other potential confounding variables, including
gender distribution, age at onset, medication dose, global
symptoms, negative symptoms, or positive symptoms,
showed a pattern consistent with the observed medication
effects. These variables are therefore unlikely to explain the
differences in cortical thickness effect sizes across the anti-
psychotic medication groups on their own, although more
complex interactions could exist. In contrast to thinner cortex,
smaller cortical surface area in individuals with schizophrenia
appears to be a more global phenomenon associated with the
disease, but not with its severity or its treatment. It is possible
that more focal cortical surface area effects are obfuscated
through the averaging of measurements within DK atlas re-
gions; vertexwise analyses may have higher power for
detecting and localizing such effects.
This study found signiﬁcant group-by-age interactions on
cortical thickness in the bilateral temporal pole regions only,
with a stronger negative correlation between age and cortical
thickness in individuals with schizophrenia than in healthy
volunteers. In addition, this study found that earlier age at
onset and longer duration of illness were associated with
thinner cortical thickness in the insula only. These ﬁndings
corroborate reported longitudinal ﬁndings of lower cortical
volumes at illness onset as well as progressive volume decline
in the temporal pole and insula in individuals with schizo-
phrenia (64,65) and individuals at ultra-high risk for psychosis
(66). Given our results, these volume declines may reﬂect
cortical thinning rather than cortical surface area reduction.
While our ﬁndings may suggest that there are few differential
effects of age on cortical thickness between individuals with
schizophrenia and healthy volunteers, we must keep in mind
that age effects on thickness across a large age range are
nonlinear (67) and that this meta-analysis combines linear age
effects across multiple independent cross-sectional cohorts of
various ages. Longitudinal studies are better poised to address
the question of differential effects of age and duration of illness
on cortical thickness in schizophrenia, and some have
observed steeper rates of cortical thinning in multiple regionshiatry November 1, 2018; 84:644–654 www.sobp.org/journal 649
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ENIGMA Schizophrenia Working Group members are actively
working on pooling longitudinal studies for a meta-analysis to
further address these questions.
Taken together, these ﬁndings may suggest that cortical
surface area developmental trajectories in psychosis may be
predominantly inﬂuenced by early neurodevelopmental,
perhaps predominantly genetic, factors. In contrast, cortical
thickness, in addition to likely being inﬂuenced by different
genes (13,14), may be more plastic and also inﬂuenced by
additional environmental and neurodegenerative factors (e.g.,
treatment, cannabis use, age) (68).
This study found signiﬁcant widespread associations be-
tween standardized medication doses (chlorpromazine equiv-
alents) and cortical thickness but not cortical surface area. This
ﬁnding is consistent with and extends a prior meta-regression
analysis, which reported that higher medication doses are
associated with smaller gray matter volume (51). Given our
results, the association with volume is likely due to cortical
thickness rather than surface area. The ﬁnding is also
consistent with the larger effect sizes for individuals with
schizophrenia who were on antipsychotic medications
compared with individuals who were not. An alternative inter-
pretation may be that more severely ill patients receive higher
doses of medication given the observed signiﬁcant associa-
tions between symptom severity and regional cortical thick-
ness. However, consistent with medication dose effects on
cortical thickness, we found that signiﬁcant associations be-
tween chlorpromazine dose equivalent and cortical thickness
were still observed in post hoc partial correlation analyses that
statistically controlled for negative symptom severity. In this
analysis, we opted to control for negative rather than positive
symptom severity, as negative symptoms tend to be less
inﬂuenced by medication dose than positive symptoms.
We caution that the likelihood that antipsychotic medica-
tions are associated with thinner cortex in individuals with
schizophrenia should by no means be interpreted as a
contraindication for their use in treating patients with severe
mental illnesses, including schizophrenia. In fact, a recent
study found that medication treatment was associated with
thinner cortex and better behavioral performance on a cogni-
tive control task (26% higher d0-context score) (24). Most
importantly, antipsychotic medications tend to successfully
treat severely debilitating psychotic symptoms, reduce relapse
risk following a ﬁrst-episode break (69), and reduce suicide risk
(70). As such, they play a critical role in the treatment of
psychosis.
Similar published meta-analyses in bipolar disorder and
major depressive disorder, with the same study design and
analytical methods, found thinner bilateral frontal, temporal,
and parietal lobe cortex in individuals with bipolar disorder with
evidence for divergent effects of medication treatments (71)
and thinner regional cortex in adults with major depressive
disorder and smaller total and regional cortical surface area in
adolescents with major depressive disorder (72). Taken
together, these very-large-scale studies suggest both similar-
ities and differences in cortical abnormalities observed among
these three major psychiatric illnesses.
To our knowledge, this is the ﬁrst meta-analysis of cortical
thickness and surface area abnormalities in schizophrenia. Only650 Biological Psychiatry November 1, 2018; 84:644–654 www.sobp.oone other schizophrenia study has provided a comprehensive
listing of Cohen’s d effect sizes for regional cortical thickness
abnormalities comparing individuals with schizophrenia, non-ill
ﬁrst-degree relatives, and healthy volunteers (1).
The major strength of the study is its large sample size,
which provides sufﬁcient power to detect even small effects
(e.g., symptom associations). Weaknesses include the
following: 1) the group of unmedicated individuals with
schizophrenia does not distinguish never-medicated from un-
medicated at time of scan, leaving effect sizes for medication-
naïve subjects to be determined; 2) despite the large total
sample size, many regional thickness differences between
medication subgroups did not survive multiple comparison
correction; 3) this study does not examine possible group
differences in brain lateralization, though such analyses will be
reported on separately; and 4) the analysis of chlorpromazine
equivalents did not dissociate ﬁrst-generation and second-
generation antipsychotic medications, which may have
dissociable effects on cortical thickness (51,72). Finally, while
this meta-analysis is unique in that it standardized image
analysis methods across sites, any meta-analysis, including
this one, is limited by sources of variation inherent to the
analysis of retrospectively collected samples that cannot be
fully controlled for. Sample differences include the use of
different scanners and different assessments or processes to
arrive at diagnosis, age at onset, duration of illness, medication
dose and adherence, etc. Meta-analyses control for these
differences by summing within-site effects across sites,
providing generalized mean effect sizes. Similar to other meta-
analyses, this meta-analysis does not control for all variance in
assessments that can lower power to detect effects.
Taken together, the ﬁndings from this meta-analysis sug-
gest that thinner cortex in schizophrenia shows regional
speciﬁcity and is affected by the illness, its severity, and
treatments with antipsychotic medications, whereas smaller
cortical surface area is mainly inﬂuenced by widespread ef-
fects of the illness possibly mainly inﬂuenced by develop-
mental processes. In the context of ENIGMA, these ﬁndings
suggest that schizophrenia genetic association studies
employing cortical thickness as a quantitative trait may need to
control for medication effects, whereas studies that employ
cortical surface area as a quantitative trait may not need to
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